NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Cannabics Pharmaceuticals Inc (STU: 8C8)

 
8C8 Technical Analysis
5
As on 31st Mar 2022 8C8 STOCK Price closed @ 0.07 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 0.20 & Strong Sell for SHORT-TERM with Stoploss of 0.20 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

8C8STOCK Price

Open 0.08 Change Price %
High 0.08 1 Day 0.00 0.00
Low 0.07 1 Week 0.01 16.67
Close 0.07 1 Month 0.00 0.00
Volume 5000 1 Year -0.07 -50.00
52 Week High 0.47 | 52 Week Low 0.06
 
STU Germany Most Active Stocks
WDI 0.05 -37.50%
WDI 0.05 -37.50%
WDI 0.05 -37.50%
WDI 0.05 -37.50%
WDI 0.05 -37.50%
TINC 0.01 -1.50%
PGF 19.13 -90.20%
PGF 19.13 -90.20%
DMJ 0.17 6.25%
DMJ 0.17 6.25%
 
STU Germany Top Gainers Stocks
PPK 0.03 36625.00%
PPK 0.03 36625.00%
PPK 0.03 36625.00%
PCBK 10.60 2020.00%
PCBK 10.60 2020.00%
336P 9.32 1882.98%
336P 9.32 1882.98%
YBOC 1.74 1640.00%
YBOC 1.74 1640.00%
WSE 0.02 635.29%
 
STU Germany Top Losers Stocks
OKU 41.40 -99.73%
OKU 41.40 -99.73%
KMK 0.08 -99.46%
KMK 0.08 -99.46%
KMK 0.08 -99.46%
XCD 50.89 -96.92%
XCD 50.89 -96.92%
XCD 50.89 -96.92%
XCD 50.89 -96.92%
RWA 28.60 -96.06%
 
 
8C8
Daily Charts
8C8
Intraday Charts
Whats New @
Bazaartrend
8C8
Free Analysis
 
8C8 Important Levels Intraday
RESISTANCE0.09
RESISTANCE0.08
RESISTANCE0.08
RESISTANCE0.08
SUPPORT0.06
SUPPORT0.06
SUPPORT0.06
SUPPORT0.05
 
8C8 Forecast May 2024
4th UP Forecast0.42
3rd UP Forecast0.31
2nd UP Forecast0.24
1st UP Forecast0.17
1st DOWN Forecast-0.03
2nd DOWN Forecast-0.1
3rd DOWN Forecast-0.17
4th DOWN Forecast-0.28
 
8C8 Weekly Forecast
4th UP Forecast0.11
3rd UP Forecast0.10
2nd UP Forecast0.09
1st UP Forecast0.08
1st DOWN Forecast0.06
2nd DOWN Forecast0.05
3rd DOWN Forecast0.04
4th DOWN Forecast0.03
 
8C8 Forecast2024
4th UP Forecast0.88
3rd UP Forecast0.62
2nd UP Forecast0.46
1st UP Forecast0.3
1st DOWN Forecast-0.16
2nd DOWN Forecast-0.32
3rd DOWN Forecast-0.48
4th DOWN Forecast-0.74
 
 
8C8 Other Details
Segment EQ
Market Capital 17903224.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
8C8 Address
8C8
 
8C8 Latest News
 
Your Comments and Response on Cannabics Pharmaceuticals Inc
 
8C8 Business Profile
Cannabics Pharmaceuticals Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel cannabinoid-based products and technologies for the treatment of cancer. The company focuses on developing and marketing bioinformatic delivery systems for cannabinoids, personalized medicine therapies, and procedures based on cannabis originated compounds and bioinformatics tools. Its lead product candidate is RCC-33, an oral capsule containing a formulation of cannabinoids for the treatment of colorectal cancer. The company is also developing Cannabics SR, a lipid-based capsule containing a standardized formulation of cannabinoids for the treatment of cancer anorexia-cachexia syndrome; and Cannabics CDx, a drug sensitivity test for cannabinoid-based cancer therapies. The company was formerly known as American Mining Corporation and changed its name to Cannabics Pharmaceuticals Inc. in May 2014. Cannabics Pharmaceuticals Inc. was founded in 2004 and is based in Bethesda, Maryland. Cannabics Pharmaceuticals Inc. is a subsidiary of Cannabics Inc. Address: #3 Bethesda Metro Center, Bethesda, MD, United States, 20814
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service